Termeer: "It can't go on forever"

Genzyme's CEO spent a good part of Monday burnishing the prospects of their experimental MS drug alemtuzumab, and thereby the value of the big biotech. With Sanofi so far unwilling to budge from its $69 offer, and Genzyme just as insistent on refusing to entertain such a price, Henri Termeer was limited to making fresh enthusiastic noises about a possible contingent value rights deal. But for now there's nothing new on prospective talks with Sanofi. "Clearly," said Termeer, "we will have conversations at the right moment...It can't go on forever."Story

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.